J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G – 2/1/23

J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)

From: BuyandBill.com <info@buyandbill.com> 

To: [customer]

Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)
 

Effective January 1, 2023:


J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from

The Centers for Medicare and Medicaid (CMS)1

HCPCS

Code

HCPCS Code

Descriptor

NDC

Number

How

Supplied

APC Per HCPCS Unit (1 mg)

HCPCS Units Per Package

J1932

injection, lanreotide, (Cipla), 1 mg

69097-0870-67

Lanreotide Acetate Subcutaneous Solution 120/MG/.05mL

$60.378

120


Please contact us @ Account.Management@Cipla.com
 


© Copyright 2023 Cipla USA Inc. All rights reserved


January 2023   CUSAI-09292022-01

References: 1. https://www.cms.gov/license/ama?file=/files/zip/january-2023-opps-addendum-b.zip